More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$7.36B
EPS
0.41
P/E ratio
41.4
Price to sales
2.22
Dividend yield
--
Beta
1.248099
Previous close
$21.23
Today's open
$21.12
Day's range
$20.75 - $21.23
52 week range
$11.39 - $22.07
show more
CEO
Chirag Patel
Employees
8700
Headquarters
Bridgewater, NJ
Exchange
Nasdaq Global Select
Shares outstanding
348412726
Issue type
Common Stock
Healthcare
Pharmaceuticals
Amneal: Buy More After Impressive Q3 Results, As Active Drug Pipeline Keeps Growing
Amneal Pharmaceuticals gets a buy reaffirmed, despite its sharp rally, supported by a robust pipeline, niche demand, improving margins, and projected upside. Amneal delivered a fourth consecutive earnings beat, with Q3 revenue up 10% and higher FY26 revenue guidance. Kashiv integration and biosimilars offer growth potential, while positive operating cash flow and an improving operating margin support earnings quality.
Seeking Alpha • Nov 17, 2026

Amneal Announces European Approval of Adcomfo® (Omalizumab), a Biosimilar to XOLAIR®
BRIDGEWATER, N.J., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the European Commission (EC) has granted marketing authorization for Adcomfo® (omalizumab), a biosimilar to XOLAIR®.
GlobeNewsWire • a day ago

Amneal Named BioSpace 2027 Best Place to Work, Ranking No.1 Among Large Employers
BRIDGEWATER, N.J., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that it has been named a BioSpace 2027 Best Place to Work, earning the No.1 ranking among large employers in the life sciences industry.
GlobeNewsWire • Nov 10, 2026

AMRX Q3 Earnings & Sales Beat Estimates, FY'26 Guidance Raised
Amneal tops Q3 estimates as strong Affordable Medicines and Specialty growth drives higher 2026 guidance and boosts its growth outlook.
Zacks Investment Research • Nov 4, 2026

What Amneal Pharmaceuticals (AMRX) Said on Its Q3 Earnings Call
Amneal Pharmaceuticals NASDAQ: AMRX reported third-quarter 2026 revenue of $863 million, up 10% from a year earlier, as growth in affordable medicines and specialty products more than offset an expected decline at its AvKARE business. Adjusted EBITDA rose 30% to $207 million, while adjusted earnings per share increased 53% to $0.26.
MarketBeat • Nov 3, 2026

Amneal Pharmaceuticals, Inc. (AMRX) Q3 2026 Earnings Call Transcript
Amneal Pharmaceuticals, Inc. (AMRX) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 3, 2026

Amneal Reports Third Quarter 2026 Financial Results
– Q3 2026 Net Revenue of $863 million ; GAAP Net Loss of $22 million ; Diluted Loss per Share of $(0.06) – – Adjusted EBITDA of $207 million ; Adjusted Diluted EPS of $0.26 – – Updating 2026 Full Year Guidance –
GlobeNewsWire • Nov 3, 2026

Amneal Pharmaceuticals (AMRX) Q3 Earnings and Revenues Top Estimates
Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.17 per share a year ago.
Zacks Investment Research • Nov 3, 2026

Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks Investment Research • Nov 3, 2026

Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?
Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research • Oct 27, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Amneal Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.